Loading data for GSK.L — first visit, this takes a few seconds.

Alert

GSK (GSK.L)

LSE: GSK.L · Real-Time Price · USD

1,869.00

-27.00 (-1.42%)

At close: Aug 12, 2026, 4:25 PM

-1.42% (1D)

No data available

Bid	n/a
Market Cap	74.86B
Revenue (ttm)	33.2B
Net Income (ttm)	4.82B
Beta	0.29
EPS (ttm)	1.18
PE Ratio (ttm)	15.84
Forward PE	9.72
P/B (ttm)	4.24
P/S (ttm)	2.25
Earnings Date	Oct 28, 2026

Ask	n/a
Volume	3,831
Avg. Volume (20D)	7,854,636
Open	n/a
Previous Close	1896.00
Day's Range	n/a - n/a
52-Week Range	n/a - 2282.00
Analyst	n/a
Price Target	n/a
Dividends	$0.68 (3.59%)
Ex-Dividend Date	Aug 13, 2026

About GSK.L

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respirator...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jul 1, 1988

Employees 66,841

Stock Exchange LSE

Ticker Symbol GSK.L

Website https://www.gsk.com

Full Company Profile

Financial Performance

In 2025, GSK's revenue was 32.67B, an increase of 4.11% compared to the previous year's 31.38B. Earnings were 5.72B, an increase of 121.98%.

Financial numbers in GBp Financial Statements

Earnings Surprise

GSK has released their quarterly earnings on Jul 28, 2026:

Revenue of $8.41B misses estimates by $0, with 5.30% YoY growth.

EPS of 0.51 exceeds estimates by 0.04, with 8.51% YoY growth.

Next Earnings Release

GSK is scheduled to release its earnings on Oct 28, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

1 week ago · Bloomberg

Trump Plans to Sign Order on Splitting Up Combined Measles Shot

(Bloomberg) -- President Donald Trump is expected to sign an executive order Monday that would recommend breaking up the combined measles, mumps and rubella vaccine into three separate shots, accordin...

1 week ago · Zacks

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

2 weeks ago · Simply Wall St.

GSK (LSE:GSK) Opens Cambridge Research Hub And Teams Up With Relation Therapeutics

GSK (LSE:GSK) plans to establish a new global R&D centre on the Cambridge Biomedical Campus in the UK. The site is expected to accommodate more than 1,000 scientists and support closer work with nearb...

2 weeks ago · Zacks

IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.

2 weeks ago · GuruFocus.com

GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ...

GSK PLC (GSK) reports Q2 sales up 5% to over GBP8.4 billion and launches a GBP1.9 billion cost-saving program, but lowers 2026 EPS guidance due to Nuvalent acquisition costs.

Page 1 of 2